Alnylam Execs Downplay Importance of Silence Therapeutics' Zamore IP
August 12, 2010
Alnylam Execs Downplay Importance of Silence Therapeutics' Zamore IP
During a conference call held to discuss Alnylam's second-quarter financial results, the company also provided some details on its biologics manufacturing initiative.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Novartis, Alcon Join Alnylam in Opposing Silence Patent in Europe
July 28, 2011 / Gene Silencing News - Alnylam Files Opposition Against Silence Patent in Europe
November 18, 2010 / Gene Silencing News - Silence Responds to Alnylam European Patent Claims
March 15, 2012 / Gene Silencing News - USPTO Upholds Silence's 'Zamore Design Rules' Patents
December 15, 2011 / Gene Silencing News - Silence Therapeutics CEO Dismisses Alnylam's Criticism of Zamore Patent Portfolio
August 12, 2010 / Gene Silencing News